December 6, 2018 5:58pm
After every big sell-off, the oversold end up overbought as bottoms are in demand
How many times, can I be right – more than most!
Out and about: Global Blood therapeutics (GBT +$1.22 or +2.68% to $46.67) proposes offering to sell $150 M in shares; Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. MiMedx (MDXG -$1.75 or -59.32%) get hammered on news of more unreliable financial statements causing a 25% reduction in force (RIF) of employees as it promotes executives and auditor Ernst&Young resigns.
Pre-open indications: 10 HITs and 4 MISS
Investors should be reading about the facts and figures in evidence – be a subscriber!
Members only. Please login.